14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $5.34 $19.02 Tuesday, 7th May 2024 OTLK stock ended at $8.21. This is 3.41% less than the trading day before Monday, 6th May 2024. During the day the stock fluctuated 7.10% from a day low at $8.17 to a day high of $8.75.
90 days $17.30 $19.02
52 weeks $16.32 $20.85

Historical Outlook Therapeutics Inc. prices

Date Open High Low Close Volume
Apr 02, 2024 $10.33 $10.86 $8.85 $9.70 1 014 177
Apr 01, 2024 $12.36 $12.85 $10.00 $10.26 1 179 293
Mar 28, 2024 $9.39 $12.70 $9.39 $11.94 1 543 665
Mar 27, 2024 $9.36 $10.55 $8.77 $9.37 1 466 273
Mar 26, 2024 $8.14 $8.97 $8.13 $8.68 410 687
Mar 25, 2024 $8.74 $8.92 $7.70 $8.51 827 619
Mar 22, 2024 $10.77 $11.72 $8.31 $8.63 20 963 008
Mar 21, 2024 $6.82 $7.74 $6.80 $7.04 275 136
Mar 20, 2024 $7.20 $7.46 $6.74 $6.78 277 372
Mar 19, 2024 $7.59 $7.72 $7.11 $7.41 202 514
Mar 18, 2024 $8.09 $8.42 $7.31 $7.79 391 430
Mar 15, 2024 $5.64 $10.72 $5.62 $8.24 2 252 201
Mar 14, 2024 $6.41 $6.73 $5.04 $5.73 566 653
Mar 13, 2024 $0.330 $0.347 $0.309 $0.323 3 441 445
Mar 12, 2024 $0.370 $0.384 $0.320 $0.350 4 323 724
Mar 11, 2024 $0.400 $0.400 $0.383 $0.391 984 122
Mar 08, 2024 $0.410 $0.411 $0.382 $0.395 1 234 314
Mar 07, 2024 $0.412 $0.420 $0.390 $0.411 1 164 480
Mar 06, 2024 $0.414 $0.420 $0.396 $0.405 780 343
Mar 05, 2024 $0.427 $0.427 $0.390 $0.396 1 698 460
Mar 04, 2024 $0.420 $0.430 $0.410 $0.423 988 555
Mar 01, 2024 $0.439 $0.440 $0.400 $0.406 1 643 444
Feb 29, 2024 $0.440 $0.450 $0.435 $0.437 848 050
Feb 28, 2024 $0.443 $0.450 $0.435 $0.438 619 562
Feb 27, 2024 $0.450 $0.455 $0.430 $0.443 803 839
Click to get the best stock tips daily for free!

About Outlook Therapeutics Inc.

Outlook Therapeutics. Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and lice... OTLK Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT